| |
|
SHS Newsletter – To open this newsletter in your browser, please click here.
|
| |
|
|
|
| |
June 2016
|
|
|
|
|
|
| |
| |
|
Dear Sir or Madam,
|
| |
This time around, we would particularly like to provide you with some insight in to the market activities of several SHS investments. The dental company TRI, for example, is entering the US market after having attained FDA approval. And our drug-delivery investment AMW is currently intensifying its capacities in order to serve the market.
Tremendous potential still exists on the regulatory side of things when it comes to ensuring growth in the area of medical technology. SHS Partner Reinhilde Spatscheck provides further details on this in her analysis.
You will also get to know the new managing director of puracon GmbH. We asked her for an interview and asked about her plans for growth.
I hope you enjoy reading,
|
| |
|
| |
|
Hubertus Leonhardt
|
|
|
|
| |
| |
|
Topics
|
| |
| • |
Awakening innovative strength
|
| |
|
|
|
| • |
AMW delivers first drug
|
| |
|
|
| • |
Puracon: "we want to grow!"
|
| |
|
|
| • |
SIS Medical hosts symposium and appoints a top-notch advisory board
|
| |
|
|
| • |
TRI dental implants receive FDA approval
|
| |
|
|
|
| • |
SHS at the MedTech Investing Europe Conference
|
| |
|
|
| • |
What's in store for molecular diagnostics?
|
| |
|
|
|
|
|
| • |
Jobs at SHS portfolio companies
|
| |
|
|
|
| • |
Selected press starting in March 2016
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
| |
| Awakening innovative strength |
| |
| The regulation of medical devices is growing step by step. At the same time, innovation is more important than ever for our health care system to ensure provision of the right solutions for an aging society. Reinhilde Spatscheck describes the barriers facing young innovative companies in this regard. |
| |
|
Read more »
|
| |
|
|
.jpeg "Spatscheck_final_grün.jpg")
|
|
|
| |
|
|
| |
Author: Reinhilde Spatscheck, Managing Partner at SHS
|
|
| |
|
|
|
|
|
|
| |
| |
| AMW delivers first drug |
| |
At the end of 2015, AMW received approval of its goserelin implants in several countries. AMW is the only company to date aside from the original manufacturer to receive approval for all dosages. Drug delivery implants protect patients, because they do away with the necessity for oral intake. AMW is expanding its production capacity to meet the expected demand.
|
| |
|
Read more »
|
| |
|
|
.jpeg "AMW_gekürzt")
|
|
|
| |
|
|
| |
AMW delivers first implants and boosts production
|
|
| |
|
|
|
| |
| |
| |
| Puracon: "we want to grow!" |
| |
Managing Director of puracon GmbH, Ruth Geßner, explains which products and services puracon offers, what makes the difference for customers and the company's future plans.
|
| |
|
Read more »
|
| |
|
|
|
|
|
| |
|
|
| |
Ruth Ch. Geßner, Managing Director at puracon GmbH
|
|
| |
|
|
|
| |
| |
| |
| SIS Medical hosts symposium and appoints a top-notch advisory board |
| |
High-pressure balloon catheters were the focus of the SIS Medical symposium at the industry event for interventional cardiology, EuroPCR. Many physicians along with distribution partners and interested parties obtained information about the advantages of treatment using high-pressure balloon catheters. And SIS has also made a second step into the future. The company will be intensifying its research efforts with a top-notch advisory board.
|
| |
|
Read more »
|
| |
|
|
.jpeg "SIS EuroPCR")
|
|
|
| |
|
|
| |
SIS Medical Boost at EuroPCR
|
|
| |
|
|
|
| |
| |
| |
| TRI dental implants receive FDA approval |
| |
As of December 2015, TRI can sell its dental implant systems in the United States. In global terms, this is a majorstep because the FDA is often an important reference. And TRI is also attracting attention due to its new packaging, which allows for grabbing the content in a single step and thus guarantees the highest possible level of surface hygiene.
Here an animation of the TRI® Pod » |
| |
|
Read more »
|
| |
|
|
.jpeg "TRI Implantat")
|
|
|
| |
|
|
| |
The innovative octaI implant made by TRI
|
|
| |
|
|
|
|
|
|
| |
| |
| SHS at the MedTech Investing Europe Conference |
| |
| Investment manager Manfred Ulmer-Weber explained strategies for commercializing growth companies at the MedTech Investing Europe Conference. |
| |
|
Read more »
|
| |
|
|
|
|
|
| |
| |
| |
| What's in store for molecular diagnostics? |
| |
| DNA diagnostics has great market potential amounting to over $19 billion - reason enough for SHS to take a detailed look at the topic. To do this, the SHS team met with Dr. Helge Lubenow, who is a proven expert on diagnostics companies, and discussed Companion Diagnostics, Point of Care Testing and other related topics with her. |
| |
|
Read more »
|
| |
|
|
.jpeg "Dr. Helge Lubenow")
|
|
|
| |
|
|
| |
Dr. Helge Lubenow of Agos Consulting
|
|
| |
|
|
|
|
|
|
| |
| |
| Jobs at SHS |
| |
Managing Director/MBI candidate (m/f) for medical technology, succession solution
Read more »
Internships for students
Read more » |
| |
|
|
|
| |
| |
| |
| Jobs at SHS portfolio companies |
| |
Project Manager Research & Development (m/f)
Read more »
Manager Regulatory Affairs (m/f)
Read more »
Strategic Sales Manager (m/f)
Read more »
Head of Sales (m/f)
Read more »
General Manager (m/f) Cardiovascular
Read more »
Project and design engineers in the fields of chemometrics methods and analytics, electronics and laser spectroscopy (m/f)
Read more » |
| |
|
|
|
|
|
|
| |
| |
| Selected press starting in March 2016 |
| |
We have compiled a selection of relevant articles about us and our portfolio companies here.
|
| |
BioMedTech regional, March 2016: "SHS übernimmt Verpackungsspezialist puracon" (SHS acquires packaging specialist puracon)
Funds advised by SHS have acquired the packaging specialist puracon. The company assembles and packages sterile medical devices and implants in GMP certified clean rooms. In addition to this, puracon advises its customers on all regulatory issues. The investment is already the sixth in the fourth fund, which focuses on expansion financing, changes of shareholders and succession situations.
Read more »
GoingPublic Magazin, 02/2016 "Personalisierte Medizin" (Personalized Medicine), April 2016: "Der Stoffwechsel in der Diagnostik- so individuell wie sein Patient" (Metabolism in diagnostics - as individual as its patients)
Even after a kidney transplant, the period of uncertainty does not end for patients as they wonder how the body will respond to the new organ. Investigations within the context of follow-ups are time consuming and sometimes unpleasant. numares has set its sights on limiting the use of invasive kidney biopsies using a urine test and identifying any complications at an early stage to respond faster.
Read more »
Börsen-Zeitung, June 4th, 2016: "Deutschland wagt zu wenig in Venture-Capital-Regulierung" (Germany risks too little with regard to venture capital regulation)
Germany's prosperity is largely based on constant innovation and new competitive products. Great potential exists for this due to excellent research facilities, but legislation is making it hard for young founders to raise sufficient capital for their businesses. Reinhilde Spatscheck explains why this is the case in her guest article for Börsen-Zeitung.
Read more »
Welt am Sonntag, 05.06.2016: "Crash auf Raten" (Crash in installments)
Startups with multi-billion dollar valuations are called unicorns because they were so rare for a long time. In recent years, their number has grown rapidly and now there are more than 160 of them. And some of them were valued too euphorically as indicated by recent devaluations seen in subsequent funding rounds. Hubertus Leonhardt is not surprised by this as he also views several other valuations as too high. He explains how he arrives at this assessment in the Welt am Sonntag newspaper.
Read more »
|
| |
|
|
|
|
|
| |
|
|
| |
|
|
| |
Investment focus
|
|
| |
|
|
| |
| Sector: |
|
life sciences (medical technology, diagnostics, applied technologies, industrial biotechnology/pharmaceutical industry; no drug development) |
| Geographical Focus: |
|
Germany, Austria, Switzerland |
| Reasons for investment: |
|
growth capital, strengthening equity, MBO/MBI, change of shareholders/succession, M&A financing, spin-off |
| Company situation: |
|
growth/expansion, succession/company sale, internationalization; operating profit may be negative for growth, or for technology-related reasons |
| Transaction value and investment size: |
|
transaction value: up to € 100 mn; investment amount SHS IV:
€ 2-20 mn, with a co-investor from the SHS-network up to € 50 mn |
| Investment types: |
|
majorities or minorities, equity & financial instruments similar to equity |
|
|
| |
|
|
| |
|
|
|
|
|
| |
|
|
| |
|
The SHS Newsletter is
published by:
SHS Gesellschaft für Beteiligungsmanagement mbH
|
|
Bismarckstrasse 12
72072 Tuebingen
Germany
www.shs-capital.eu
|
|
Tel +49 7071 9169-0
Fax +49 7071 9169-190
To unsubscribe the newsletter, please click here.
|
|
|
| |
|
|
| |
Editorial team: SHS Gesellschaft für Beteiligungsmanagement mbH, Ira Wülfing Kommunikation GmbH | Design and technical realisation: UNIBRAND GmbH
To open this newsletter as a PDF file please click here.
|
|
| |
|
|
|
|
| |
|